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Background
Targeted iron oxide nanoparticles are easily detected with
MR by their exaggerated signal dropout. Recent advanced
techniques are emerging to visualize iron oxide particles
as "hot spots" rather than signal dearth. For background
blood pool clearance, a typical delay of 24 hr is required
between contrast treatment and imaging. Although tar-
geted USPIO or MION agents bind endothelial cell sur-
face markers, they also further extravasate into plaque,
binding macrophages or other intraplaque constituents
during the 24-hour wait. This confounds the morpholog-
ical source of the MR signal. Moreover, in coronary MR
imaging_where high temporal and spatial resolution are
required and inherent anatomic magnetic susceptibility
heterogeneity masks that of the iron oxide agents_dark
spot T2-weighted gradient echo imaging of targeted iron
oxides is challenging and has not yet been demonstrated.
The objective of this research was to develop an intravas-
cular, fibrin-specific iron oxide agent useful for early,
rapid detection and quantification of ruptured plaque in
coronary arteries with MRI.
Methods
Superparamagnetic nanocolloid particles were developed
with the core having multiple magnetite nanoparticles
suspended in vegetable oil and encased in a lipid mem-
brane. The MR T1 and T2 properties of the nanocolloid
were determined using serial dilutions of the agent from
100% to 1% and MR acquisitions including Look-Locker
(inversion recovery) and multi-echo gradient-echo tech-
niques. To assess signal on both T1- and T2-weighted
images, functionalized particles were targeted to clot sur-
faces with biotin and an antibody targeted to fibrin-rich
thrombi (n = 7) suspended in saline in vitro; one clot
served as an untreated control reference. Imaging of the
clots was performed at 1.5 T using a high-resolution (0.3
× 0.3 × 1.2 mm3) 3D T1-weighted turbo spin-echo
sequence for ROI analysis and lower-resolution (1 × 1 × 5
mm3) gradient-echo imaging, both T1-and T2*-weighted,
for visual inspection.
Results
The average particle size and zeta potential of the nanocol-
loid were approximately 140 nm and -23 mV, respec-
tively. The iron concentration, measured by mass
spectrometry, was ~2000 μg/g of emulsion. In solution,
T1 and T2 effects varied with concentration with minimal
T1 effect at 1% dilution. At higher concentrations in solu-
tion, the T2* effects dominated and produced dark dis-
torted images typical to iron oxide agents. When bound to
the outer surface of the fibrin-rich clots, the nanocolloid
produced bright enhancement on T1-weighted imaging
(SNR = 26); whereas the control clot, which received no
agent, was poorly discerned from surrounding saline
(SNR = 10). On T2-weighted images, characteristic
"blooming" effects were produced by the bound agent but
not on the control. (See Figure 1) Using pharmacokinetic
parameters and models for similar lipid-encapsulated
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emulsion nanoparticles, the systemic concentration of
this nanocolloid agent for a typical in vivo application was
projected to be less than the 1% dilution upon injection
and approximately 0.03% of this concentration in 20
minutes, which suggest that, although the particles are
constrained to the vasculature, the background levels will
be negligible soon after injection leaving only the bound
agent visible. Moreover, the dual T1 and T2 contrast fea-
tures of this agent obviates the need for pre-contrast base-
line images.
Conclusion
These larger, fibrin-specific superparamagnetic nanocol-
loids may provide highly sensitive, bright-contrast detec-
tion of microthrombi exposed in ruptured plaque. The
combination of high MR sensitivity and the imaging
speed advantages of short T1-weighted pulse sequences
may overcome the cardiac motion barrier to MR coronary
molecular imaging.
MR images of fibrin-rich clots in salineFigure 1
MR images of fibrin-rich clots in saline. (A) the control clot is 
poorly visualized on high resolution T1 (shown) and T2 (not 
shown). (B) High resolution, T1-weighted fast spin echo 
images show the bright enhancement caused by the iron oxid 
nanocolloid bound to the clot surface. Lower resolution T1-
weighted gradient echo imaging (C) also shows enhancement 
which turns into typical magnetic susceptibility blooming arti-
fact on T2-weighted gradient echo images (D).Page 2 of 2
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